Strategic Relationship with Redox to Expand EHR Integration Capabilities
BRISBANE, Australia and CARLSBAD, Calif., July 20, 2016 /PRNewswire/ — ImpediMed Limited (ASX: IPD) announced today a partnership with Redox to expand the capabilities of electronic health record (EHR) integration for ImpediMed’s next generation medical device.
The new device will use ImpediMed’s proprietary bioimpedance spectroscopy (BIS) technology to measure, monitor and manage fluid status and body composition in clinical and at-home settings.
Through Redox’s modern application programming interface (API) for EHR integration, ImpediMed can streamline the interoperability of its device with multiple EHR vendors, including Epic, Cerner, eClinicalWorks, Allscripts, Meditech, NextGen, and any other major EHR to create a user-friendly and data rich technology solution.
“Given our expansion into health centers around the world, the need to be fully integrated into the ecosystem of complex electronic health record systems is critical,” said Richard Carreon, Managing Director and CEO of ImpediMed. “The partnership with Redox gives our next generation medical device an immediate head start with a solution that allows our patients and clinicians the ability to have ImpediMed health data at their fingertips.”
ImpediMed’s BIS technology provides a precise, rapid and repeatable snapshot of a person’s lean body mass, fat mass, total body mass and intra-and-extracellular fluid.
Having access to historical health data can help health care providers better detect and manage chronic disease in patients, improving outcomes and reducing the costs of care.
Founded in 2014 in Madison, Wisconsin, Redox provides healthcare data interoperability for cloud-based software vendors seeking to exchange data with EHRs hosted on-premise at health system data centers.
Their modern API dramatically expands the scope and quality of patient care by allowing the secure exchange of data between health systems and cloud applications.
Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men.
For additional information, visit www.impedimed.com.